MGNX
MacroGenics Inc
NASDAQ: MGNX · HEALTHCARE · BIOTECHNOLOGY
$3.08
+4.76% today
Updated 2026-04-30
Market cap
$193.86M
P/E ratio
—
P/S ratio
1.30x
EPS (TTM)
$-1.18
Dividend yield
—
52W range
$1 – $4
Volume
1.1M
MacroGenics Inc (MGNX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-49.90%
Operating margin
-29.30%
ROE
-87.00%
ROA
-17.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $47.05M | $6.72M | 100.00% | 11.16% | 14.28% |
| 2012 | $59.65M | $8.36M | 100.00% | 13.76% | 14.02% |
| 2013 | $56.75M | $-260835.00 | 100.00% | 0.64% | -0.46% |
| 2014 | $47.26M | $-38.31M | 100.00% | -81.07% | -81.06% |
| 2015 | $100.85M | $-20.14M | 100.00% | -20.01% | -19.97% |
| 2016 | $86.58M | $-58.53M | 100.00% | -69.35% | -67.60% |
| 2017 | $155.52M | $-19.63M | 100.00% | -14.24% | -12.62% |
| 2018 | $60.12M | $-171.45M | 100.00% | -284.77% | -285.18% |
| 2019 | $62.02M | $-151.81M | 100.00% | -285.67% | -244.76% |
| 2020 | $97.76M | $-117.78M | 100.00% | -134.06% | -120.48% |
| 2021 | $75.64M | $-190.86M | 96.50% | -268.09% | -252.31% |
| 2022 | $151.94M | $-120.02M | 95.14% | -79.91% | -78.99% |
| 2023 | $57.19M | $-9.06M | 85.62% | -294.17% | -15.84% |
| 2024 | $148.34M | $-66.97M | 91.71% | -74.54% | -45.14% |
| 2025 | $149.50M | $-74.62M | 71.12% | -48.72% | -49.91% |